Patricia da Silva

Patricia da Silva serves as a key procurement lead within the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, where she manages complex research and technology acquisitions aligned with NIDA’s mission to advance scientific understanding of substance use disorders. She oversees the acquisition of specialized laboratory equipment, biotechnology research services, and precision instrumentation critical to neurobiological and behavioral studies. Her portfolio emphasizes translational research support, ensuring that cutting-edge scientific needs are met through compliant, timely contracting processes that align with federal research funding priorities. She maintains longstanding relationships with leading academic and research institutions, including McLean Hospital Corporation, the University of Maryland Baltimore, the University of Miami, the University of Pittsburgh, and the Icahn School of Medicine at Mount Sinai. These partnerships typically involve cooperative research agreements, service contracts for clinical trials, and instrumentation procurement to support high-throughput data collection and analysis in addiction research. Her contracting approach prioritizes institutional expertise in neuroscience, pharmacology, and behavioral science, fostering collaborative, mission-driven vendor relationships. Patricia’s procurement patterns reflect a strong preference for open competition, with 93.8% of awards issued without set-aside restrictions, indicating a focus on technical merit and scientific capability over socioeconomic classifications. While small business participation is limited, the 6.3% allocated to Total Small Business Set-Asides demonstrates a measured, performance-based commitment to small business engagement where competitive capability aligns with research demands. Her primary procurement focus centers on NAICS 334516 (analytical laboratory instrument manufacturing) and 811210 (electronic and precision equipment repair and maintenance), reflecting deep expertise in procuring mass spectrometers, neuroimaging systems, and diagnostic instrumentation. She also regularly acquires biotechnology R&D services (NAICS 541714) and biological product manufacturing (NAICS 325414), underscoring her technical proficiency in supporting advanced drug discovery, neurochemical analysis, and translational research infrastructure.